The sale of COVID-19 vaccines helped Moderna’s (MRNA) revenue soar over the past few quarters. The shares plummeted nearly 14% after the disappointing results of its seasonal flu shot on December 10. So, let’s discuss if it is wise to buy the dip in the stock with the advent of the COVID-19 omicron variant. Keep reading. Moderna , Inc.’s (NASDAQ:) COVID-19 vaccine was the second vaccine approved for EUA by the U.S. FDA. Investors are still concerned. Pfizer Inc.’s (NYSE:) dominance in the vaccine space. MRNA’s COVID-19 vaccine is not yet approved for adolescents as regulators continue to study the rare risk of heart inflammation. Also, last month, the company’s CEO Stéphane Bancel said that existing COVID-19 vaccines are unlikely to be as effective against the omicron coronavirus variant.

MRNA stock has lost 42.8% in price over the past month to close Friday’s trading session at $257.06. MRNA received multiple orders for the COVID-19 vaccine. MRNA announced on December 1 that it had revised its supply agreement for 60 million doses with the U.K. Its COVID-19 vaccination is however the only product that has been commercialized by the company, and its other products are in their clinical trial phases.

MRNA’s stock declined nearly 10% in price on December 1, after the company lost a patent dispute. Also, MRNA’s CEO recently sold 19,000 shares. So, MRNA’s near-term prospects look uncertain.

Continue reading on StockNews